These experimental data suggest that HSCs and leukemic cells are protected from RA signaling by CYP26 activity in the bone marrow niche, which provides a plausible explanation as to why clinical studies failed to demonstrate any benefit from the addition of ATRA to treatment regimens in non-APL AML [2,99]. Here, CYP26A1 is linked to acute myeloid leukemia.